Australian biopharmaceutical giant CSL Ltd said it would buy Swiss drugmaker Vifor Pharma AG for $11.7 billion, as it aims to diversify beyond its blood plasma collection business that took a hit from COVID-19 curbs.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
